** Eye-drug developer Kodiak Sciences' KOD.O shares down 0.6% before the bell at $23.98 after $160 mln follow-on priced
** Palo Alto, California-based biotech late Tues said it sold ~7 mln shares at $23, a 4.7% discount to last sale
** KOD shares closed up nearly 5% on Tues after co late Mon commenced 6 mln share offering
** Co, which has ~53 mln shares outstanding, plans to use net proceeds for working capital and general corp purposes, per the prospectus
** JP Morgan, Jefferies, Evercore and UBS are joint bookrunners
** Through Tues close, KOD shares surged nearly seven-fold over the past six months, putting them up ~143% YTD
** Avg rating among 8 analysts is "buy" and median PT is $24, per LSEG data
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))
Comments